|
|
|||
|
|||
|
|
|||
|
namenda memantine hci |
|||
|
|
|||
|
|||
 
|
|||
|
|
|||
|
namenda memantine hci Generic Name: memantine HCl Date of Approval: Manufacturer: Treatment for: The U.S namenda memantine hci. Food and Drug Administration (FDA) has approved Namenda (memantineHCl) for the treatment of moderate to severe Alzheimer's disease namenda memantine hci. Namenda isthe first NMDA receptor antagonist to be approved for Alzheimer's disease andis also the only therapy approved for the treatment of moderate to severe Alzheimer'sdisease. Namenda's FDA approval is based on the Agency's review of safety and efficacydata from two U.S namenda memantine hci. placebo-controlled Phase III clinical trials and an earliertrial conducted among nursing home patients in Europe namenda memantine hci. Phase III data includeda 28-week monotherapy study of 252 patients published earlier this year in theNew England Journal of Medicine and a six-month, 401-patient study of Namendawhen used together with an ongoing regimen of the commonly used Alzheimer'sagent, donepezil namenda memantine hci. In trials, patients treated with Namenda scored higher onmeasures of cognition, daily function, and/or global performance namenda memantine hci. This developmentprogram for memantine was a joint effort between Forest and its licensor, MerzPharmaceuticals, who obtained centralized approval for memantine in the EuropeanUnion in 2002 namenda memantine hci. Merz Pharmaceuticals is a specialty pharmaceutical company dedicatedto research and development in the fields of neurology and psychiatry. In clinical trials, Namenda has been safe and well tolerated namenda memantine hci. The most commonadverse events observed in clinical trials are dizziness, headache, constipation,and confusion namenda memantine hci. Once available in pharmacies, Namenda will be administered orallyat a recommended dose of 10 mg BID following a four-week titration. Alzheimer's is a progressive disease of the brain and it is the most commontype of dementia namenda memantine hci. The term dementia is used to describe the progressive lossof cognitive, intellectual, or functional abilities namenda memantine hci. Published reports projectthat by 2010 more than 5.1 million people in the United States will have Alzheimer'sdisease namenda memantine hci. Currently, all Alzheimer's medications approved in the United Statesbelong to a class of agents called acetylcholinesterase inhibitors, which areindicated for patients with mild to moderate symptoms of the disease namenda memantine hci. Namendais the only approved therapy in the United States for moderate to severe Alzheimer'sdisease.
Namenda (memantine HCl) is the first of a new class of medications for Alzheimer'sdisease with a mechanism of action distinct from currently available drugs namenda memantine hci. Namenda is a low to moderate affinity NMDA (N-methyl-D- aspartate) receptorantagonist namenda memantine hci. It is thought that overexcitation of NMDA receptors by the neurotransmitterglutamate may play a role in Alzheimer's disease since glutamate plays an integralrole in the neural pathways associated with learning and memory namenda memantine hci. The excitotoxicityproduced by abnormal levels of glutamate is thought to be responsible for neuronalcell dysfunction and the eventual cell death observed in Alzheimer's disease namenda memantine hci. Namenda is thought to selectively block the excitotoxic effects associated withabnormal transmission of glutamate, while allowing for the physiological transmissionassociated with normal cell functioning. |
|||
 
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
| nnamenda memantine hci naamenda memantine hci nammenda memantine hci nameenda memantine hci namennda memantine hci namendda memantine hci namendaa memantine hci namenda memantine hci namenda mmemantine hci namenda meemantine hci namenda memmantine hci namenda memaantine hci namenda memanntine hci namenda memanttine hci namenda memantiine hci namenda memantinne hci namenda memantinee hci namenda memantine hci namenda memantine hhci namenda memantine hcci namenda memantine hcii amenda memantine hci nmenda memantine hci naenda memantine hci namnda memantine hci nameda memantine hci namena memantine hci namend memantine hci namendamemantine hci namenda emantine hci namenda mmantine hci namenda meantine hci namenda memntine hci namenda mematine hci namenda memanine hci namenda memantne hci namenda memantie hci namenda memantin hci namenda memantinehci namenda memantine ci namenda memantine hi namenda memantine hc n amenda memantine hci na menda memantine hci nam enda memantine hci name nda memantine hci namen da memantine hci namend a memantine hci namenda memantine hci namenda memantine hci namenda m emantine hci namenda me mantine hci namenda mem antine hci namenda mema ntine hci namenda meman tine hci namenda memant ine hci namenda memanti ne hci namenda memantin e hci namenda memantine hci namenda memantine hci namenda memantine h ci namenda memantine hc i namenda memantine hci anmenda memantine hci nmaenda memantine hci naemnda memantine hci namneda memantine hci namedna memantine hci namenad memantine hci namend amemantine hci namendam emantine hci namenda emmantine hci namenda mmeantine hci namenda meamntine hci namenda memnatine hci namenda mematnine hci namenda memanitne hci namenda memantnie hci namenda memantien hci namenda memantin ehci namenda memantineh ci namenda memantine chi namenda memantine hic anamenda memantine hci thenamenda memantine hci namenda memantine hci | |||
|
|
|||
|
|
|||
|
|
|||
|
Copyright 2005 D-S LTD. |
